- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04706923
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection (ATHENA)
May 1, 2024 updated by: SymBio Pharmaceuticals
A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection
The purpose of this study is to determine the Dose from the safety and tolerability of intravenous Brincidofovir (BCV, SyB V-1901) using multiple ascending doses in subjects with Adenovirus infection.
Study Overview
Detailed Description
This is a Phase IIa, open-label, multiple ascending dose confirmation, multicenter study to evaluate the safety and tolerability of intravenous Brincidofovir (BCV, SyB V-1901) 0.2 mg/kg, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW (Cohorts 1 to 4) in adult and pediatric subjects with AdV viremia.
A total of 24 subjects aged 2 months and older will be enrolled: 6 subjects to each Cohort.
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kohji Shimasaki
- Phone Number: +81-3-6684-6616
- Email: MedInfo@symbiopharma.com
Study Contact Backup
- Name: Rochelle Maher
- Phone Number: +1-917-656-6951
- Email: maher@symbiopharma.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- Research Site
-
Los Angeles, California, United States, 90027
- Recruiting
- Research Site
-
San Francisco, California, United States, 94158
- Recruiting
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Recruiting
- University of Nebraska Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Research Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- Recruiting
- St. Jude Children's Research Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Not yet recruiting
- MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 months and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female, aged 2 months and older at the time of informed consent.
- AdV DNA viremia >10,000 copies/mL from a single sample, or 2 samples greater than 48 hours apart with the second result higher than the first and both greater than 1000 copies/mL, from the data obtained from the designated central virology laboratory of the local laboratory using the blood sample(s) collected informed consent has been obtained and within 7 days prior to Day 1 (AdV DNA viremia results collected within the 7 day window, but prior to consent may be used if the Informed Consent Form (ICF) signed by the subject provides approval) .
- Either (a) have disseminated AdV disease or (b) have an underlying immunocompromised state, and have asymptomatic AdV infection or localized AdV disease.
- In the judgment of the investigator, be in a serious condition to be treated with intravenous cidofovir for AdV.
Exclusion Criteria:
- Subjects who weigh ≥120 kg.
- NIH/NCI CTCAE (United States [US] National Institutes of Health [NIH]/National Cancer Institute) Grade 2 or higher diarrhea (i.e., increase of ≥ 4 stools per day over usual pre-transplant stool output) within 7 days prior to Day 1.
- NIH Stage 4 acute GVHD of the skin (i.e., generalized erythroderma with bullous formation) within 7 days prior to Day 1.
- NIH Stage 2 or higher acute GVHD of the liver function (i.e., bilirubin >3 mg/dL [SI: >51 μmol/L]) within 7 days prior to Day 1.
- NIH Stage 2 or higher acute GVHD of the gut (i.e., diarrhea >556 mL/m2/day for pediatric subjects [or >1000 mL/day for young adults as applicable, at centers in the United States only], or severe abdominal pain with or without ileus) within 7 days prior to Day 1.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BCV 0.2mg/kg BIW
BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
|
BCV 0.2 mg/kg BIW, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW via IV infusion for 2 hours
|
Experimental: BCV 0.3mg/kg BIW
BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
|
BCV 0.2 mg/kg BIW, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW via IV infusion for 2 hours
|
Experimental: BCV 0.4 mg/kg BIW
BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
|
BCV 0.2 mg/kg BIW, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW via IV infusion for 2 hours
|
Experimental: BCV 0.4 mg/kg QW
BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 for a minimum of 4 weeks.
|
BCV 0.2 mg/kg BIW, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW via IV infusion for 2 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with BCV treatment-related adverse events as assessed by NCI CTCAE v5.0
Time Frame: From initiation of BCV administration up to 4 weeks
|
From initiation of BCV administration up to 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change AdV viremia in plasma measured from baseline up to 4 weeks
Time Frame: From initiation of BCV administration up to 4 weeks
|
From initiation of BCV administration up to 4 weeks
|
Change of Time-averaged [AdV AAUC] for AdV viremia in plasma from baseline up to 4 weeks
Time Frame: From initiation of BCV administration up to 4 weeks
|
From initiation of BCV administration up to 4 weeks
|
Peak AdV viral load in plasma after onset of AdV viremia up to 4 weeks
Time Frame: From initiation of BCV administration up to 4 weeks
|
From initiation of BCV administration up to 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 16, 2021
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
January 5, 2021
First Submitted That Met QC Criteria
January 11, 2021
First Posted (Actual)
January 13, 2021
Study Record Updates
Last Update Posted (Actual)
May 3, 2024
Last Update Submitted That Met QC Criteria
May 1, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCV-PA01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenovirus Infection
-
AlloVirBaylor College of Medicine; The Methodist Hospital Research Institute; Center...WithdrawnAdenovirus InfectionUnited States
-
Central Hospital, Nancy, FranceCompleted
-
ChimerixCompleted
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedCytomegalovirus Infection | Adenovirus InfectionUnited States
-
Children's National Research InstituteM.D. Anderson Cancer CenterCompleted
-
St. Anna KinderkrebsforschungWithdrawnCytomegalovirus Infection | Adenovirus InfectionAustria
-
Baylor College of MedicineM.D. Anderson Cancer Center; Massachusetts General Hospital; National Heart,... and other collaboratorsCompletedEBV Infection | Adenovirus InfectionUnited States
-
AlloVirBaylor College of Medicine; The Methodist Hospital Research Institute; Center...Completed
-
Baylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI); The Methodist Hospital Research... and other collaboratorsCompletedAdenovirus InfectionUnited States
-
Mari DallasRecruitingAllogeneic Hematopoietic Stem Cell TransplantationUnited States
Clinical Trials on BCV
-
ChimerixCompletedDouble-stranded DNA VirusUnited States
-
SymBio PharmaceuticalsRecruitingBK Virus Infection | Kidney Transplantation | NephropathyAustralia, Japan
-
ChimerixNo longer available
-
ChimerixCompletedAdenovirus DiseaseUnited States
-
ChimerixCompletedCytomegalovirus InfectionUnited States
-
Olatec Therapeutics LLCRadboud University Medical CenterTerminated
-
ChimerixCompletedAdenovirus InfectionUnited States
-
ChimerixCompletedHepatic ImpairmentUnited States
-
ChimerixWithdrawnAdenovirusUnited States, Spain, Italy